PUMA BIOTECHNOLOGY, INC. (PBYI) Financial Statements
PUMA BIOTECHNOLOGY, INC. (PBYI) reported trailing twelve-month revenue of $231.2M (down 2.9% year on year) and net income of $26.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $41.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PBYIPUMA BIOTECHNOLOGY, INC.Follow PBYI — free
—
Price chart with a free account
- Market cap
- 568.9M
- P/E TTM
- 21.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.7 | 251.0 | 272.3 | 225.1 | 253.2 | 228.0 | 235.6 | 230.5 | 228.4 | 231.2 | |
| Gross profit | 22.1 | 216.4 | 235.4 | 185.7 | 189.5 | 172.9 | 173.0 | 166.1 | 170.2 | 173.0 | |
| Research & development | 207.8 | 164.9 | 132.9 | 97.7 | 71.9 | 52.2 | 50.4 | 54.9 | 62.1 | 71.4 | |
| Operating income | -292.4 | -94.7 | -39.0 | -30.4 | 1.3 | 23.7 | 32.6 | 31.0 | 37.3 | 30.4 | |
| Pre-tax income | -292.0 | -113.6 | -75.5 | -59.8 | -28.8 | 0.5 | 22.7 | 24.1 | 35.8 | 31.2 | |
| Income tax | 0.0 | 0.0 | 0.1 | 0.2 | 0.3 | 0.5 | 1.1 | -6.2 | 4.7 | — | |
| Net income | -292.0 | -113.6 | -75.6 | -60.0 | -29.1 | 0.0 | 21.6 | 30.3 | 31.1 | 26.7 | |
| Diluted EPS ($) | -7.85 | -2.99 | -1.95 | -1.52 | — | 0.00 | 0.45 | 0.62 | 0.61 | 0.52 | |
| Diluted shares (mn) | — | — | — | — | — | 44.9 | 47.6 | 49.1 | 50.7 | — |
USD millions · SEC XBRL
PUMA BIOTECHNOLOGY, INC. — questions
- What is PUMA BIOTECHNOLOGY, INC.'s revenue?
- $231.2M over the twelve months to 2026-06-30, down 2.9% year on year, from its 10-Q and 10-K filings.
- What is PUMA BIOTECHNOLOGY, INC.'s net income?
- $26.7M over the twelve months to 2026-06-30.
- What is PUMA BIOTECHNOLOGY, INC.'s free cash flow?
- $41.2M over the twelve months to 2026-06-30.
- What are PUMA BIOTECHNOLOGY, INC.'s diluted earnings per share?
- $0.52 over the twelve months to 2026-06-30.
Every figure on this page comes from PUMA BIOTECHNOLOGY, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.